BMY Stock Summary and Trading Ideas (Bristol-Myers Squibb Company | NYSE:BMY)

Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.

Bristol-Myers Squibb Company trades on the NYSE stock market under the symbol BMY.

As of May 1, 2026, BMY stock price declined to $58.22 with 13,083,989 million shares trading.

BMY has a beta of 0.60, meaning it tends to be less sensitive to market movements. BMY has a correlation of 0.12 to the broad based SPY ETF.

BMY has a market cap of $118.87 billion. This is considered a Large Cap stock.

Last quarter Bristol-Myers Squibb Company reported $11 billion in Revenue and $1.58 earnings per share. This beat revenue expectation by $571 million and exceeded earnings estimates by $.15.

In the last 3 years, BMY traded as high as $69.10 and as low as $39.35.

The top ETF exchange traded funds that BMY belongs to (by Net Assets): VTI, VOO, SCHD, IVV, SPY.

BMY has underperformed the market in the last year with a price return of +22.4% while the SPY ETF gained +30.4%. However, in the short term, BMY had mixed performance relative to the market. It has outperformed in the last 3 months, returning +6.9% vs +4.4% return in SPY. But in the last 2 weeks, BMY shares have been beat by the market, returning -3.2% compared to an SPY return of +1.5%.

BMY support price is $59.56 and resistance is $61.62 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BMY shares will trade within this expected range on the day.